ClinicalTrials.gg
RecruitingNCT04839003ReALUpdated Apr 16, 2026

A Registry of AL Amyloidosis (ReAL)

An observational study in AL Amyloidosis, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia — 6 open to participants now, 6 under way, none of them phase 3. Immunoglobulin Light-chain Amyloidosis · Fondazione IRCCS Policlinico San Matteo di Pavia.

Started
2020
with 1 other
Observational
7 of 13
6 open now
Registered
6th of 13
by date

Among the 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia, this one is one of 2 that started in 2020, is one of 7 observational ones, and was the 6th registered.

Immunoglobulin Light-chain Amyloidosis

239 studies on the registry are indexed under Immunoglobulin Light-chain Amyloidosis; 63 are open to participants now.

Browse Immunoglobulin Light-chain Amyloidosis studies →

Open to participants now

6 of the 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 49 Immunoglobulin Light-chain Amyloidosis studies recruiting now, 34 (69%) set no upper age limit and 3 (6%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia, or all of them as a file.
02

Study summary

The purpose of this protocol is to generate a large registry of patients with AL amyloidosis.

Read the detailed description

Thanks to this registry, it will be possible to collect data at diagnosis and during follow up, in order to be able to describe the natural history of AL amyloidosis in a real-world setting and to define and validate prognostic models, response and relapse criteria applicable at any point of the disease.

03

Conditions studied

  • AL Amyloidosis

Keywords

  • amyloidosis
  • prognosis
  • registry
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be entered the database pending on expressing an informed consent of the use of their data for research purposes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. diagnosis of systemic AL amyloidosis;
  2. treatment-naïve (pre-treatment data collected at participating center available for retrospective part);
  3. age ≥18 years;
  4. ability to understand and willingness to sign an (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted);
  5. planned (or ongoing) follow-up at participating center.

Exclusion criteria

Exclusion Criteria:

  1. non-AL amyloidosis;
  2. previous treatment for AL amyloidosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Creation of a registry of patients with AL amyloidosis

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2020 (actual). Primary completion is estimated for May 2027, 87 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2021
First posted
Apr 9, 2021
StartActual
Feb 27, 2020
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04839003
Responsible party
Giovanni Palladini (Principal Investigator, Fondazione IRCCS Policlinico San Matteo di Pavia) — Principal investigator
First posted
Apr 9, 2021
Start date
Feb 27, 2020
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Apr 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion